Atorvastatin + Atorvastatin + Atorvastatin

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Dyslipidemias

Conditions

Dyslipidemias

Trial Timeline

Aug 1, 2003 → Apr 1, 2004

NCT ID

NCT00647543

About Atorvastatin + Atorvastatin + Atorvastatin

Atorvastatin + Atorvastatin + Atorvastatin is a approved stage product being developed by Pfizer for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT00647543. Target conditions include Dyslipidemias.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00645151	Approved	Completed	Apr 1, 2004	Feb 1, 2005	Dyslipidemias
NCT00645424	Approved	Completed	Dec 1, 2003	Oct 1, 2004	Hyperlipidemias
NCT00647543	Approved	Completed	Aug 1, 2003	Apr 1, 2004	Dyslipidemias

Competing Products

15 competing products in Dyslipidemias

See all competitors

Product	Company	Stage	Hype Score
LY3202328 + Placebo + Atorvastatin + Simvastatin	Eli Lilly	Phase 1	33
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg	Yuhan	Approved	85
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC	Eli Lilly	Phase 1	33
LY3885125 + Placebo	Eli Lilly	Phase 1	33
LY3561774 + Placebo	Eli Lilly	Phase 1	33
LY3561774 + Placebo	Eli Lilly	Phase 2	52
LY2484595 + Placebo + Atorvastatin	Eli Lilly	Phase 2	52
Atorvastatin + Atorvastatin	Pfizer	Approved	84
Atorvastatin	Pfizer	Approved	84
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	84
Vupanorsen + Placebo	Pfizer	Phase 2	51
Atorvastatin	Pfizer	Approved	84
GWP42003 + GWP42003 + GWP42004 + Placebo	Jazz Pharmaceuticals	Phase 2	49
ARO-APOC3	Arrowhead Pharmaceuticals	Phase 2	49
ARO-ANG3 + sterile normal saline (0.9% NaCl)	Arrowhead Pharmaceuticals	Phase 1	30

Other Products from Pfizer